AR125084A1 - Agonistas del receptor de glucocorticoides novedosos - Google Patents
Agonistas del receptor de glucocorticoides novedososInfo
- Publication number
- AR125084A1 AR125084A1 ARP220100591A ARP220100591A AR125084A1 AR 125084 A1 AR125084 A1 AR 125084A1 AR P220100591 A ARP220100591 A AR P220100591A AR P220100591 A ARP220100591 A AR P220100591A AR 125084 A1 AR125084 A1 AR 125084A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- acceptable salt
- receptor agonists
- Prior art date
Links
- 229940124750 glucocorticoid receptor agonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000005777 Lupus Nephritis Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/0026—Oxygen-containing hetero ring cyclic ketals
- C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J17/005—Glycosides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona un compuesto de fórmula (1) en donde R es hidrógeno, -P(=O)(OH)₂, o un resto del grupo de fórmulas (2), o una sal farmacéuticamente aceptable de este, en donde el compuesto de fórmula (1), o sal farmacéuticamente aceptable de este, es útil para tratar enfermedades autoinmunitarias e inflamatorias, tales como dermatitis atópica, artritis reumatoide, lupus eritematoso sistémico, nefritis lúpica y enfermedad inflamatoria intestinal. Reivindicación 1: Un compuesto de la fórmula (1) en donde R es hidrógeno, -P(=O)(OH)₂, o un resto del grupo de fórmulas (2), o una sal farmacéuticamente aceptable de este.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163164603P | 2021-03-23 | 2021-03-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125084A1 true AR125084A1 (es) | 2023-06-07 |
Family
ID=81308191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100591A AR125084A1 (es) | 2021-03-23 | 2022-03-15 | Agonistas del receptor de glucocorticoides novedosos |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12227538B2 (es) |
| EP (1) | EP4314006B1 (es) |
| JP (1) | JP7696440B2 (es) |
| KR (1) | KR102892606B1 (es) |
| CN (1) | CN116964067A (es) |
| AR (1) | AR125084A1 (es) |
| AU (1) | AU2022241660B2 (es) |
| BR (1) | BR112023016353A2 (es) |
| CA (1) | CA3209260A1 (es) |
| ES (1) | ES3015513T3 (es) |
| IL (1) | IL305242A (es) |
| MX (1) | MX2023011281A (es) |
| SA (1) | SA523450844B1 (es) |
| TW (1) | TW202304464A (es) |
| WO (1) | WO2022204100A1 (es) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0101220D0 (sv) * | 2001-04-04 | 2001-04-04 | Astrazeneca Ab | New use |
| AU2006259604A1 (en) | 2005-06-14 | 2006-12-28 | Gilead Sciences, Inc. | Substituted phenylphosphates as mutual prodrugs of steroids and beta -agonists for the treatment of pulmonary inflammation and bronchoconstriction |
| EP2225256B1 (en) * | 2007-11-30 | 2013-01-09 | Pfizer Limited | Novel glucocorticoid receptor agonists |
| TW200944540A (en) | 2007-12-21 | 2009-11-01 | Schering Corp | C20-C21 substituted glucocorticoid receptor agonists |
| RU2010133722A (ru) | 2008-02-27 | 2012-04-10 | Астразенека Аб (Se) | 16-альфа, 17-альфа-ацетальглюкокортикостероидные производные и их применение |
| CN102448978A (zh) * | 2009-05-29 | 2012-05-09 | 辉瑞有限公司 | 新颖的糖皮质激素受体激动剂 |
| EP3359194A4 (en) | 2015-10-06 | 2019-04-24 | Merck Sharp & Dohme Corp. | ANTIBODY-ACTIVE CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS |
| EP3407916B1 (en) | 2016-01-29 | 2023-12-20 | Merck Sharp & Dohme LLC | Phosphonate linkers and their use to facilitate cellular retention of compounds |
| PE20190622A1 (es) * | 2016-06-02 | 2019-04-26 | Abbvie Inc | Agonista del receptor de glucocorticoides e inmunoconjugados del mismo |
| IL307357A (en) | 2016-11-08 | 2023-11-01 | Regeneron Pharma | Steroids and their protein conjugates |
| HUE054428T2 (hu) * | 2017-12-01 | 2021-09-28 | Abbvie Inc | Glükokortikoid receptor agonista és annak immunkonjugátumai |
| SG11202004865SA (en) | 2017-12-01 | 2020-06-29 | Abbvie Inc | Anti-cd40 antibody drug conjugates |
| WO2021216913A1 (en) | 2020-04-22 | 2021-10-28 | Immunext, Inc. | Anti-human vista antibodies and use thereof |
| BR112023013247A2 (pt) * | 2021-01-07 | 2023-10-03 | Immunext Inc | Cargas úteis de esteroide, ligantes de esteroide, adcs contendo os mesmos e seus usos |
| TWI899455B (zh) * | 2021-03-23 | 2025-10-01 | 美商美國禮來大藥廠 | 糖皮質素受體激動劑 |
-
2022
- 2022-03-15 AR ARP220100591A patent/AR125084A1/es unknown
- 2022-03-15 TW TW111109388A patent/TW202304464A/zh unknown
- 2022-03-22 ES ES22716635T patent/ES3015513T3/es active Active
- 2022-03-22 AU AU2022241660A patent/AU2022241660B2/en active Active
- 2022-03-22 EP EP22716635.2A patent/EP4314006B1/en active Active
- 2022-03-22 US US17/700,910 patent/US12227538B2/en active Active
- 2022-03-22 MX MX2023011281A patent/MX2023011281A/es unknown
- 2022-03-22 JP JP2023558317A patent/JP7696440B2/ja active Active
- 2022-03-22 CA CA3209260A patent/CA3209260A1/en active Pending
- 2022-03-22 BR BR112023016353A patent/BR112023016353A2/pt unknown
- 2022-03-22 WO PCT/US2022/021285 patent/WO2022204100A1/en not_active Ceased
- 2022-03-22 CN CN202280018309.6A patent/CN116964067A/zh active Pending
- 2022-03-22 IL IL305242A patent/IL305242A/en unknown
- 2022-03-22 KR KR1020237032202A patent/KR102892606B1/ko active Active
-
2023
- 2023-09-21 SA SA523450844A patent/SA523450844B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7696440B2 (ja) | 2025-06-20 |
| KR20230148223A (ko) | 2023-10-24 |
| JP2024510775A (ja) | 2024-03-11 |
| TW202304464A (zh) | 2023-02-01 |
| EP4314006A1 (en) | 2024-02-07 |
| WO2022204100A1 (en) | 2022-09-29 |
| US12227538B2 (en) | 2025-02-18 |
| CN116964067A (zh) | 2023-10-27 |
| MX2023011281A (es) | 2023-10-04 |
| AU2022241660B2 (en) | 2024-10-10 |
| CA3209260A1 (en) | 2022-09-29 |
| ES3015513T3 (en) | 2025-05-06 |
| SA523450844B1 (ar) | 2025-04-07 |
| AU2022241660A1 (en) | 2023-09-07 |
| US20220306680A1 (en) | 2022-09-29 |
| IL305242A (en) | 2023-10-01 |
| KR102892606B1 (ko) | 2025-11-28 |
| EP4314006B1 (en) | 2025-01-22 |
| BR112023016353A2 (pt) | 2023-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020201948B2 (en) | Neuroactive steroids, compositions, and uses thereof | |
| Manna et al. | Synthesis of some pyrazole derivatives and preliminary investigation of their affinity binding to P-glycoprotein | |
| PE20180573A1 (es) | Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r) | |
| CA3070515A1 (en) | Carbamoyloxy acetic acid derivatives and their use as selective inhibitors of nlrp3 inflammasome | |
| UA77765C2 (en) | N3 alkylated derivatives of benzimidazole as mek inhibitors | |
| US20130267542A1 (en) | Histone deacetylases (hdacs) inhibitors | |
| WO2013160810A2 (en) | Novel betulinic acid derivatives as hiv inhibitors | |
| BRPI0715448A2 (pt) | Compostos de ligação heterocíclicos fxr, composição farmacêutica, uso do composto e método para preparar o composto | |
| ES3004523T3 (en) | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | |
| JP2022551067A (ja) | カンナビノイド誘導体 | |
| CA2971373A1 (fr) | Derives benzimidazoles sulfonamides en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t) | |
| UA121853C2 (uk) | Спосіб одержання інгібітору pde4 | |
| AR125084A1 (es) | Agonistas del receptor de glucocorticoides novedosos | |
| ES2687393T3 (es) | Derivados del ácido hidroxámico de isoxazolina como inhibidores de LpxC | |
| BR112020000141A2 (pt) | síntese de halicondrinas | |
| CR20230445A (es) | Anticuerpos anti-cd30l y usos de estos | |
| JP2023503330A (ja) | カンナビノイド誘導体 | |
| JP2023503601A (ja) | カンナビゲロール誘導体、およびカンナビノイド受容体モジュレーターとしてのその使用 | |
| WO2022051582A1 (en) | Sulphamoyl urea derivatives containing alkyl-oxacycloalkyl moiety and uses thereof | |
| JP6398124B2 (ja) | ２−アシルイミノピリジン誘導体の製造法 | |
| US20210171527A1 (en) | Compounds as modulators of ror gamma | |
| AR125079A1 (es) | Agonistas de receptores de glucocorticoides sustituidos con carboxi | |
| EA034063B1 (ru) | Антибактериальные средства на основе производных ципрофлоксацина | |
| CA2884806A1 (en) | An improved process for the preparation of fulvestrant | |
| Kim et al. | Novel practical synthesis of d-cycloserine |